SDGR
NASDAQSchrodinger Inc.
Price$19.98+6.76 (+51.13%)
2026-05-212026-08-25
News · 26 weeks55+60%
2026-03-012026-08-23
Mix2890d
- Insider11(39%)
- Other7(25%)
- SEC Filings6(21%)
- Earnings2(7%)
- Leadership1(4%)
- Analyst1(4%)
Latest news
25 items- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve
- ANALYSTUBS resumed coverage on Schrodinger with a new price targetUBS resumed coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00
- PRAI Found an Influenza Target That Survives Viral MutationAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c
- SECSEC Form S-8 filed by Schrodinger Inc.S-8 - Schrodinger, Inc. (0001490978) (Filer)
- SECSEC Form 10-Q filed by Schrodinger Inc.10-Q - Schrodinger, Inc. (0001490978) (Filer)
- SECSchrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports Second Quarter 2026 Financial ResultsSecond Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2026. "We are very pleased with our second quarter results, delivering ACV of $29.6 million, which represents 27% growth. Our results reflect growing industry adoption of a predict-first approach to molecular discovery," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "As biopharma navigates a rapidly evolving AI landscape and mounting pressure to optimize and accelerate the discovery of new medicines, the need to generate
- PRSchrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug DiscoverySchrödinger, Inc. (NASDAQ:SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. Building on a long-standing partnership with BMS where they routinely utilize Schrödinger’s industry-leading computational platform, the new agreement significantly expands the application of Schrödinger’s platform, empowering BMS scientists to explore more scientific possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. Under the agreement, Schrödinger will collaborate with BMS scientists on developing novel functionality within Bunsen in conjunction with
- PRSchrödinger Introduces Bunsen, an AI Co-Scientist for Molecular DiscoveryCollaboration with NVIDIA and Google Cloud Provide Additional Tools and Compute Access Schrödinger, Inc. (NASDAQ:SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By combining AI with physics-based simulation, Bunsen allows researchers to apply their expertise at greater scale, enabling them to explore more scientific possibilities, prioritize the most promising opportunities with greater confidence and accelerate discovery decisions. Advances in computer-aided drug disc
- PRAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersIssued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)USA News Group News CommentaryNEW YORK, July 23, 2026 /CNW/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk about accelerating the search for new medicines; far fewer can point to real revenue, real clients, and a business model that compounds. One small-cap AI biotech just put a set of numbers behind its version of that story, and they show a company whose pivot is starting to appear in its financials rather than only in its slide decks. The company reported full-year resu
- PRSchrödinger to Announce Second Quarter 2026 Financial Results on August 5Schrödinger, Inc. (NASDAQ:SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology,
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company’s common stock to four newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.The RSUs vest over four years, with 25 percent of such RSUs vesting
- INSIDEREVP & CFO Jain Rachit sold $13,647 worth of shares (875 units at $15.60) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,877 units (SEC Form 4) to cover taxes4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Friesner Richard gifted 679,373 shares and received a gift of 679,373 shares (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- SECSchrodinger Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Schrodinger, Inc. (0001490978) (Filer)
- INSIDERDirector Oberoi Arun was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Chodakewitz Jeffrey was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Friesner Richard was granted 8,141 shares, increasing direct ownership by 1% to 690,365 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Ginsberg Gary L was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Kapeller-Libermann Rosana was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Lynton Michael was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Sender Gary was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Thornberry Nancy was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Van Kralingen Bridget A was granted 8,141 shares, increasing direct ownership by 71% to 19,640 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
SDGR FAQ
7 questionsWhat does Schrodinger Inc. do?
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic...Where does SDGR stock trade?
Schrodinger Inc. (SDGR) is listed on NASDAQ.What sector and industry is SDGR in?
Schrodinger Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Schrodinger Inc. go public?
Schrodinger Inc. (SDGR) completed its IPO in 2020.What are analysts saying about SDGR?
Schrodinger Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $1900.00 price target on 2026-08-14. Recent price targets range from $1900.00 to $3800.00.What companies are similar to SDGR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SDGR side-by-side with any of them on Quantisnow.How can I track SDGR on Quantisnow?
Quantisnow aggregates Schrodinger Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SDGR to receive live email and push alerts on every new disclosure.